1. Academic Validation
  2. Aminopyrazole Carboxamide Bruton's Tyrosine Kinase Inhibitors. Irreversible to Reversible Covalent Reactive Group Tuning

Aminopyrazole Carboxamide Bruton's Tyrosine Kinase Inhibitors. Irreversible to Reversible Covalent Reactive Group Tuning

  • ACS Med Chem Lett. 2018 Dec 3;10(1):80-85. doi: 10.1021/acsmedchemlett.8b00461.
Mark E Schnute 1 Stephen E Benoit 1 Ingrid P Buchler 1 Nicole Caspers 2 Margaret L Grapperhaus 3 Seungil Han 2 Rajeev Hotchandani 1 Nelson Huang 1 Robert O Hughes 1 Brian M Juba 1 Kyung-Hee Kim 1 Erica Liu 1 Erin McCarthy 1 Dean Messing 1 Joy S Miyashiro 1 Shashi Mohan 1 Thomas N O'Connell 2 Jeffrey F Ohren 2 Mihir D Parikh 2 Michelle Schmidt 3 Shaun R Selness 3 John R Springer 1 Venkataraman Thanabal 2 John I Trujillo 2 Daniel P Walker 3 Zhao-Kui Wan 1 Jane M Withka 2 Arthur J Wittwer 3 Nancy L Wood 1 Li Xing 1 Christoph W Zapf 1 John Douhan 3rd 1
Affiliations

Affiliations

  • 1 Medicine Design and Inflammation and Immunology Research, Pfizer, Cambridge, Massachusetts 02139, United States.
  • 2 Medicine Design, Pfizer, Groton, Connecticut 06340, United States.
  • 3 Medicinal Chemistry and Inflammation and Immunology Research, Pfizer, St. Louis, Missouri 63017, United States.
Abstract

Potent covalent inhibitors of Bruton's tyrosine kinase (Btk) based on an aminopyrazole carboxamide scaffold have been identified. Compared to acrylamide-based covalent reactive groups leading to irreversible protein adducts, cyanamide-based reversible-covalent inhibitors provided the highest combined Btk potency and EGFR selectivity. The cyanamide covalent mechanism with Btk was confirmed through Enzyme kinetic, NMR, MS, and X-ray crystallographic studies. The lead cyanamide-based inhibitors demonstrated excellent kinome selectivity and rat pharmacokinetic properties.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-164002
    BTK Inhibitor
    Btk